136 related articles for article (PubMed ID: 10784645)
1. Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: a critique.
Hellmann K
J Clin Oncol; 2000 May; 18(9):2004-6. PubMed ID: 10784645
[No Abstract] [Full Text] [Related]
2. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology.
Schuchter LM; Hensley ML; Meropol NJ; Winer EP;
J Clin Oncol; 2002 Jun; 20(12):2895-903. PubMed ID: 12065567
[No Abstract] [Full Text] [Related]
3. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Hensley ML; Schuchter LM; Lindley C; Meropol NJ; Cohen GI; Broder G; Gradishar WJ; Green DM; Langdon RJ; Mitchell RB; Negrin R; Szatrowski TP; Thigpen JT; Von Hoff D; Wasserman TH; Winer EP; Pfister DG
J Clin Oncol; 1999 Oct; 17(10):3333-55. PubMed ID: 10506637
[TBL] [Abstract][Full Text] [Related]
4. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
5. Anaphylaxis to dexrazoxane (ICRF-187) following three previous uncomplicated infusions.
Leoni V; Santini D; Vincenzi B; Grilli C; Onori N; Tonini G
Allergy; 2004 Feb; 59(2):241. PubMed ID: 14763950
[No Abstract] [Full Text] [Related]
6. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
Hensley ML; Hagerty KL; Kewalramani T; Green DM; Meropol NJ; Wasserman TH; Cohen GI; Emami B; Gradishar WJ; Mitchell RB; Thigpen JT; Trotti A; von Hoff D; Schuchter LM
J Clin Oncol; 2009 Jan; 27(1):127-45. PubMed ID: 19018081
[TBL] [Abstract][Full Text] [Related]
7. A small prospective study of chordomas treated with radiotherapy and razoxane.
Rhomberg W; Böhler FK; Novak H; Dertinger S; Breitfellner G
Strahlenther Onkol; 2003 Apr; 179(4):249-53. PubMed ID: 12707714
[TBL] [Abstract][Full Text] [Related]
8. Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without evidence.
Hellmann K
J Clin Oncol; 2007 Oct; 25(29):4689-90; author reply 4690-1. PubMed ID: 17925567
[No Abstract] [Full Text] [Related]
9. Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors.
Hofland KF; Thougaard AV; Dejligbjerg M; Jensen LH; Kristjansen PE; Rengtved P; Sehested M; Jensen PB
Clin Cancer Res; 2005 Sep; 11(18):6722-9. PubMed ID: 16166453
[TBL] [Abstract][Full Text] [Related]
10. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
Jones RL
Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1311-7. PubMed ID: 19018683
[TBL] [Abstract][Full Text] [Related]
11. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity.
Swain SM
Semin Oncol; 1998 Aug; 25(4 Suppl 10):43-7. PubMed ID: 9768823
[TBL] [Abstract][Full Text] [Related]
12. Dexrazoxane: a second look. Prevention of anthracycline cardiotoxicity: useful for some patients.
Prescrire Int; 2008 Oct; 17(97):195. PubMed ID: 19534047
[TBL] [Abstract][Full Text] [Related]
13. Dexrazoxane does not affect treatment outcome in non-Hodgkin's lymphoma patients.
Rabinovich A; Weiss D; Weissman M; Novack V; Levi I
Am J Hematol; 2012 Aug; 87(8):830-2. PubMed ID: 22648436
[No Abstract] [Full Text] [Related]
14. Current variations in childhood cancer supportive care in the Netherlands.
Loeffen EA; Mulder RL; van de Wetering MD; Font-Gonzalez A; Abbink FC; Ball LM; Loeffen JL; Michiels EM; Segers H; Kremer LC; Tissing WJ
Cancer; 2016 Feb; 122(4):642-50. PubMed ID: 26588808
[TBL] [Abstract][Full Text] [Related]
15. Dexrazoxane for anthracycline extravasation.
Langer SW
Expert Rev Anticancer Ther; 2007 Aug; 7(8):1081-8. PubMed ID: 18028016
[TBL] [Abstract][Full Text] [Related]
16. Concomitant phase II studies of pyrazofurin and razoxane in alkylating agent-resistant cases of epithelial ovarian carcinoma.
Edmonson JH; Decker DG; Malkasian GD; Webb MJ
Cancer Treat Rep; 1981; 65(11-12):1127-9. PubMed ID: 7296557
[No Abstract] [Full Text] [Related]
17. Drug Interactions in the Treatment of Malignancy in HIV-Infected Patients.
Welz T; Wyen C; Hensel M
Oncol Res Treat; 2017; 40(3):120-127. PubMed ID: 28253501
[TBL] [Abstract][Full Text] [Related]
18. Should anthracyclines and dexrazoxane be used for children with cancer?
van Dalen EC; van den Berg H; Raphaël MF; Caron HN; Kremer LC
Lancet Oncol; 2011 Jan; 12(1):12-3. PubMed ID: 21195321
[No Abstract] [Full Text] [Related]
19. Strategies for reduction of anthracycline cardiac toxicity.
Speyer J; Wasserheit C
Semin Oncol; 1998 Oct; 25(5):525-37. PubMed ID: 9783592
[TBL] [Abstract][Full Text] [Related]
20. NIH program encourages early-career researchers: innovative researchers delve into ways to attack cancer, reduce side effects of chemotherapy.
Printz C
Cancer; 2015 Feb; 121(4):487-8. PubMed ID: 25651983
[No Abstract] [Full Text] [Related]
[Next] [New Search]
